Brentuximab vedotin (SGN-35) in a 3-year-old child with relapsed systemic anaplastic large cell lymphoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Immunoconjugates
  • Immunotoxins
  • Lymphoma, Large-Cell, Anaplastic

abstract

  • The treatment of anaplastic large cell lymphoma (ALCL) has largely relied on anthracycline-based chemotherapy. Targeted lymphoma therapy, using an anti-CD30 antibody, provides an innovative treatment modality for specific lymphomas, particularly ALCL. Brentuximab vedotin (BV; SGN-35) uses a CD30 monoclonal antibody to generate apoptosis of targeted lymphoma cells. We present a pediatric patient with ALCL who experienced second relapse after standard chemotherapy and autologous and allogeneic hematopoietic stem cell transplantation. This patient has been treated with BV as a single agent and has sustained remission for several months. BV offers a targeted treatment for relapsed ALCL, even after multiple relapses.

publication date

  • March 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1097/MPH.0b013e31828aff2c

PubMed ID

  • 23588340

Additional Document Info

start page

  • e85

end page

  • 7

volume

  • 36

number

  • 2